X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
REV-0100 is a potential therapy for patients with Stargardt disease, designed to bind and clear a toxic lipid called lipofuscin. REV-0100 was developed from research from Weill Cornell Medicine in New York City, and is covered by a granted patent.
Lead Product(s): REV-0100
Therapeutic Area: Genetic Disease Product Name: REV-0100
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
Details:
Under the terms if the agreement reVision Therapeutics gains rights for the development and commercialization of Cornell's proprietary technology for the treatment of Stargardt disease, a genetic disorder that affects central vision.
Lead Product(s): REV-0100
Therapeutic Area: Genetic Disease Product Name: REV-0100
Highest Development Status: UndisclosedProduct Type: Undisclosed
Recipient: Cornell University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
